Influvac Tetra

influenza vaccine, inactivated, quadrivalent, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It helps prevent influenza caused by the virus strains included in the vaccine in individuals six months of age and older.

GNH USA supplies Influvac Tetra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Tetra is an inactivated quadrivalent influenza vaccine that provides protection against seasonal influenza viruses. - Seasonal influenza prevention: induces immunity to the four influenza virus strains contained in the vaccine, reducing the risk of infection. - Influenza prophylaxis in adults: helps lower the incidence of laboratory‑confirmed influenza in people aged 18 years and older. - Influenza prophylaxis in children: offers protection for children from six months of age, decreasing illness severity and complications.

Common and serious adverse reactions may occur after administration of Influvac Tetra.

Common Side Effects: - Injection site pain: mild to moderate soreness at the injection site. - Redness or swelling: localized erythema or edema around the injection area. - Low‑grade fever: transient temperature rise up to 38 °C. - Headache or myalgia: mild headache or muscle aches lasting 1–2 days.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may develop within weeks after vaccination. - Seizures: infrequent occurrence, particularly in children with a history of febrile seizures.

Before administering Influvac Tetra, consider the following precautions. - Allergic history: avoid use in individuals with known severe allergy to any vaccine component. - Previous reaction: defer vaccination in persons who experienced a serious adverse event after a prior influenza vaccine. - Acute illness: postpone vaccination until recovery from moderate or severe febrile illness. - Age restrictions: ensure the recipient is at least six months old; dosing differs for specific age groups. - Immunocompromised status: vaccine may be less immunogenic; assess benefit‑risk in severely immunosuppressed patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may interact with other agents, influencing safety or effectiveness.

Major Interactions (Avoid): - Live viral vaccines: avoid co‑administration within 4 weeks due to potential interference with immune response. - Immunoglobulin therapy: concurrent use may reduce vaccine‑induced antibody production.

Moderate Interactions (Monitor Closely): - Antipyretics: prophylactic use may blunt the antibody response; consider timing after vaccination. - Anticoagulants: intramuscular injection may increase bleeding risk; apply pressure post‑injection. - Immunosuppressive drugs: may diminish immunogenicity; monitor serologic response if needed.